We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Cell Culture Technique Leads to Tailor-Made Cancer Treatments

By LabMedica International staff writers
Posted on 04 Jan 2015
A novel in situ capture and culture methodology has been developed for ex vivo expansion of circulating tumor cells (CTCs) using a three dimensional co-culture model, simulating a tumor microenvironment to support tumor development.

The potential utility of CTCs to guide clinical care in oncology patients has gained momentum with emerging micro- and nano-technologies and tumor progression and metastasis depends both on enumeration and on obtaining sufficient numbers of CTCs for downstream assays.

Scientists at the University of Michigan (Ann Arbor, MI, USA) developed the capture and culture process with a microfluidic chip device that captures cancer cells as a blood sample is pumped across it. More...
The team used a chip made of polydimethylsiloxane on a 1-inch by 3-inch glass slide. They covered the chip with microscopic posts that slow and trap cells, then coated it with antibodies that bind to the cancer cells.

Blood drawn from early lung cancer patients was flowed through the CTC-capture device at a flow rate of 1 mL/hour for 1 mL total for each device. After the cancer cells were captured on the chip, the team pumped in a growth medium mixture. They also added cancer-associated fibroblast cells. This created a three-dimensional environment that closely mimics the conditions inside the body of a cancer patient. After capture, cells also were fixed and immunofluorescently stained with labelled antibodies. The devices were scanned using a programmed inverted fluorescence microscope (Nikon, Melville, NY, USA). Positive and negative cells were designated as CTCs depending on the staining and enumerated.

The investigators used many other techniques including 3-D spheroid assays, invasion assays, sequencing, and real time polymerase chain reaction, (RT-PCR) which were analyzed on the ABI 7900HT instrument (Applied Biosystems; Foster City, CA; USA). After the cancer cells were captured on the chip, the team pumped in a mixture of collagen and Matrigel growth medium. The captured cancer cells prospered in the mixture, reproducing additional cells in 73% of tested samples. It was a dramatic improvement over earlier methods, which studied later-stage cancer patients and saw success rates of only around 20%.

Max S. Wicha, MD, distinguished professor of oncology, and coauthor of the study said, “The technology can be applied to most cancers, including breast, lung, pancreatic and others. It could enable doctors to follow the progression of each patient's disease much more closely. Cancer cells change constantly and they can quickly develop resistance to a given treatment. A device like this will enable us to follow the cancer's progression in real time. If a cancer develops resistance to one therapy, we'll be able to quickly change to a different treatment.” The study was published on December 1, 2014, in the journal Oncotarget.

Related Links:

University of Michigan  
Nikon
Applied Biosystems



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.